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Abstract: End stage liver disease due to hepatitis C virus (HCV) infection is the most common 
indication for liver transplantation (LT) worldwide. Regretfully, infection of the graft by HCV 
occurs almost universally after LT, causing chronic hepatitis and early progression to cirrhosis 
in a signiﬁ  cant proportion of recipients. Moreover, graft and patient survival are signiﬁ  cantly 
worse in patients undergoing LT for HCV-related cirrhosis than in those transplanted for other 
indications. Therefore, many LT centers consider antiviral treatment with interferon and riba-
virin the mainstay of managing recurrent HCV disease in LT recipients. The optimal time to 
start treatment is unclear. In most instances, treatment is initiated when histological evidence 
of disease recurrence, either at protocol or on-demand liver biopsies, is observed after LT. 
However, antiviral treatment initiated before LT is a potential option for some patients for two 
reasons: ﬁ  rst, clearing or suppressing HCV before LT may reduce or eliminate the risk of recur-
rent hepatitis C in the transplanted liver and thereby improve survival; second, clearing HCV 
in cirrhotic patient may halt disease progression and avoid the need for transplantation. In this 
article, the results obtained by pre-transplant antiviral regimens administered to HCV-positive 
cirrhotic patients awaiting LT are discussed.
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Chronic infection with hepatitis C virus (HCV) is the leading cause of cirrhosis and 
hepatocellular carcinoma (HCC) in Western countries and accounts for about half of the 
indications for liver transplantation (LT) worldwide (Berenguer et al 2000). Although 
LT is effective for treating decompensated cirrhosis and small HCC secondary to 
hepatitis C, HCV re-infection of the graft is virtually the rule among patients in 
whom serum HCV RNA is detectable at the time of the transplant operation (Gish 
et al 2005). Moreover, the rate of hepatic ﬁ  brosis progression is much faster in LT 
recipients with recurrent hepatitis C than in immune-competent patients with chronic 
hepatitis C (Bizollon et al 1999; Berenguer et al 2000). As a result, graft cirrhosis 
is observed in approximately 30% of HCV-positive recipients ﬁ  ve years after LT, 
resulting in 23% excess mortality and 30% excess graft loss (Forman et al 2002). 
Since the availability of donor organs is limited, and the resources invested for each 
liver transplant are increasing, strategies to improve the outcome of LT for hepatitis 
C need to be devised.
Donor and recipient factors, viral factors, and transplant-associated events have 
been linked with an increased severity of HCV disease. Considering the viral factors, 
it is well known that HCV particles circulating in the blood at the time of surgery, 
is the likely source of virus that reinfects the new graft, although other extra-hepatic 
sources of HCV may contribute (McCaughan et al 2004). Indeed some studies have 
linked a high viral load before LT with a more severe HCV recurrence after LT 
(Charlton et al 1998; Berenguer et al 2000). Thus, the strong rationale to treat HCV Therapeutics and Clinical Risk Management 2008:4(3) 600
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infection before LT, while the patient is on the waiting list, 
is that administering antiviral treatment pre-transplant may 
prevent graft re-infection, hence reducing the risk of early 
ﬁ  brosis progression in the graft and, hopefully, improving 
graft and patient survival. Moreover, HCV clearance may 
halt further disease progression among LT candidates, who 
might thus avoid or delay LT (Terrault et al 2006).
Antiviral therapy for HCV-related 
cirrhosis
Antiviral treatment of HCV-positive immune-competent 
cirrhotic patients is currently based on the combination of 
pegylated interferon α-2a (Pegasys, Roche, USA) or 2b 
(PEG-Intron, Schering Plough, USA) in association with 
ribavirin (Copegus, Roche, USA or Rebetol, Schering 
Plough, USA); in the near future, the therapeutic armamen-
tarium for hepatitis C will be expanded to include new drugs, 
such as protease and polymerase inhibitors, that are expected 
to increase the effectiveness of interferon-based treatment 
regimens (Toniutto et al 2006).
With current treatment regimens, the rates of sustained 
virological response (SVR) among cirrhotics can be as 
high as 40%–50% (Manns et al 2001; Fried et al 2002; 
Hadziyannis et al 2004; Toniutto et al 2006). However, in 
the large registration clinical trials from which these data 
were generated, patients with signs of portal hypertension 
or decompensated liver disease were not included; therefore, 
these rates cannot be extrapolated to sicker patients such as 
those on a waiting list for LT.
Antiviral therapy for HCV-related 
cirrhosis in patients awaiting liver 
transplantation
To date, four studies have investigated the efﬁ  cacy and safety 
of antiviral treatment in patients with HCV-related cirrhosis 
awaiting LT: in three, patients received interferon α-2b 
(Intron-A, Schering Plough, USA) plus ribavirin (Crippin 
et al 2002; Forns et al 2003; Everson et al 2005), and in one, 
monotherapy with standard interferon α-2b administered 
daily (Thomas et al 2003). The main clinical and virological 
features of these studies are summarized in Table 1. Further-
more, a recent study has evaluated the efﬁ  cacy and safety of 
the combination of pegylated-interferon α-2b plus ribavirin 
in patients with decompensated HCV-related cirrhosis, of 
whom some were subsequently transplanted (Iacobellis 
et al 2007).
The study by Thomas and colleagues (2003) was based 
on the aforementioned assumption that the greater the HCV 
viral load at the time of LT, the earlier clinically evident post 
transplantation HCV recurrence occurs (Charlton et al 1998). 
Table 1 Summary of the main clinical and virological features of studies evaluating the antiviral therapy in HCV-positive cirrhotic 
patients awaiting liver transplantation
Author (year) N. of pts Treatment regimen Mean
duration
(months)
On treatment 
viral response 
(%)
SVR
(%)
HCV 
recurrence
(%)
Adverse 
events§ 
(%)
(Crippin et al 2002) 15 Group A (3 pts): IFN 1 
MU qd
2 33 NA 100 87
Group B (6 pts): IFN 3 
MU qd
Group C (6 pts): IFN 1 
MU qd plus RIB 400 mg 
bid
(Thomas et al 2003) 20 IFN 5 MU qd 14 60 NA 67 15
(Forns et al 2003) 30 IFN 3 MU qd plus RIB 800 
mg qd
33 0 N A 3 3 3 0
(Everson et al 2005) 102 IFN 1.5 MU tiw plus RIB 
600 mg qd
NR 46 24 20 65
IFN increased to 3 MU 
tiw at week 2
RIB increased by 200 mg 
weekly after week 4
Abbreviations: IFN, interferon; RIB, ribavirin; NR, not reported; SVR, sustained viral response; NA, not applicable.
Notes: §Events that caused dosage reduction or discontinuation of antiviral therapy.Therapeutics and Clinical Risk Management 2008:4(3) 601
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Twenty HCV-positive cirrhotic patients (67% infected by 
genotype 1) were treated with an aggressive schedule using 
interferon α-2b 5 MU daily dose for a mean of 14 months 
before LT. The proportion of patients who cleared the virus 
during treatment was 60% and, more importantly, 4 of the 
12 patients (33%) who achieved this result did not have 
evidence of HCV recurrence after LT during a mean follow 
up of 34 months. This antiviral regimen was generally 
well tolerated, although all patients required granulocyte-
stimulating factors (GCSF) in order to maintain their white 
blood cell count above 1500 cells/mm3. In the study conducted 
by Crippin and colleagues (2002), 15 HCV-positive cirrhotic 
patients in Child-Pugh class B or C, approaching the top of 
their waiting lists, were randomized to receive, until LT, a 
regimen based either 1 MU or 3 MU three times weekly of 
standard interferon α-2b, or the association of 3 MU of stan-
dard interferon α-2b three times weekly plus 400 mg twice 
daily of ribavirin. It is important to note that in this study less 
than half of the screened patients met the inclusion criteria, 
thrombocytopenia and leukopenia being the most common 
reasons for exclusion. Absence of circulating HCV RNA 
by a sensitive polymerase chain reaction assay at the time 
of LT was achieved by 5/15 (33%) patients; three of these 
patients had HCV RNA levels undetectable by bDNA signal 
ampliﬁ  cation at baseline. Two further patients underwent 
LT during antiviral therapy, one with circulating HCV RNA 
undetectable by bDNA signal ampliﬁ  cation but detectable 
by PCR, and one who achieved only a small (less than one 
log10) decline in HCV RNA levels; in both patients, HCV 
infection recurred after LT. The study was interrupted early 
because a relevant proportion of patients experienced seri-
ous adverse events during treatment, leading the authors to 
conclude that patients with advanced liver disease should 
not be candidate for antiviral therapy. More encouraging 
results have been reported in the study conducted by Forns 
and colleagues (2003), in which 30 HCV-positive cirrhotic 
patients (25 infected by genotype 1) were treated, until the 
transplant operation, with the combination of 3 MU daily of 
interferon α-2b plus 800 mg daily of ribavirin, started when 
the expected time for LT was less than four months. At the 
time of their inclusion in the study, half of the patients were 
in Child-Pugh class B or C. Among the 9 (30%) patients 
who achieved SVR and underwent LT, 6 (67%) remained 
free of HCV recurrence after a mean follow-up of 46 weeks. 
In analogy to what occurs outside the LT setting, the fac-
tors independently associated with SVR were the viral load 
at baseline and its decrease 2 log10 at week 4 of therapy. 
Side effects related to antiviral treatment were frequent and 
caused a dose reduction in 19 (63%) of the 30 treated patients. 
In the more recent study by Everson and colleagues (2005), 
102 patients with HCV-related cirrhosis received escalat-
ing doses of standard interferon and ribavirin. The initial 
treatment schedule required interferon α-2b 1.5 MU three 
times weekly, plus ribavirin 600 mg daily. The interferon 
dose was increased to 3 MU three times weekly at week two, 
whereas the ribavirin dose started to be escalated only after 
week 4. Sixty-eight (67%) of the patients were in Child-Pugh 
class B or C, and the vast majority (70%) were infected by 
HCV genotype 1. The overall end of treatment and SVR 
rates were 46% and 24% respectively. Signiﬁ  cantly higher 
virological response rates were observed in HCV genotype 
2 and 3 infected patients in comparison to those infected by 
genotype 1 (60% Vs 11%). Eighty percent of the patients 
who achieved SVR and underwent LT were free of HCV 
recurrence in the graft after a mean follow-up of more than 
6 months; however, only a small proportion of those listed 
and treated (15 out of 90 patients) were transplanted. Despite 
the use of erythropoietin and GCSF, adverse events requir-
ing discontinuation of therapy occurred in 20% of patients. 
Finally, in a very recent study by Iacobellis and colleagues 
(2007), aimed to investigate the efficacy and safety of 
combination therapy with pegylated interferon α-2b plus 
ribavirin in treating HCV-related decompensated cirrhosis, 
129 patients were enrolled. The inclusion criteria were HCV-
related cirrhosis and hospital admission for ascites, variceal 
bleeding or hepatic encephalopathy. One month after the 
resolution, of the decompensated event with appropriate 
management, all patients were offered antiviral therapy, after 
explanation of expected beneﬁ  ts and potential risks. About 
half (66 patients) agreed to be treated whereas the remain-
ing 63 patients, who did not, served as controls. The most 
common diagnosis at admission was ascites; 71% and 23% 
were classiﬁ  ed in Child-Pugh class B and C respectively. 
The mean MELD score value was 14, but only 24% had a 
MELD score 18. About two thirds were infected by HCV 
genotype 1 and 22% of the treated patients were older than 
65 years. Baseline characteristics of treated and untreated 
patients did not differ signiﬁ  cantly, with the exception of 
hemoglobin levels, which were higher in treated patients 
than in controls. The treatment regimen employed was the 
combination of weekly 1.0 µg/Kg body weight of pegylated-
interferon α-2b with oral ribavirin at a daily dosage of 800 
or 1000 mg for body weights  or 75 Kg, respectively, for 
24 weeks. By intention-to-treat analysis, SVR was achieved 
in 43.5% of patients infected by HCV genotypes 2 and 3, and 
in 7% of those infected by genotypes 1 and 4. Only 41% of Therapeutics and Clinical Risk Management 2008:4(3) 602
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treated patients completed the intended schedule of treatment. 
In fact, despite the liberal use of GCSF and erythropoietin, 
in 38% of the patients dosages of both pegylated interferon 
and ribavirin had to be reduced for hematological toxicity. 
Twenty-one percent of patients discontinued treatment for 
severe adverse events, mainly severe urinary or respiratory 
tract infections, occurring more frequently in Child-Pugh 
class C patients and in cases with neutrophil counts at base-
line 2100/mm3. Although the mortality rates on treatment 
did not differ between patients and controls, a trend towards 
a higher probability of death, related to severe infection 
episodes, was observed in the treated group. At the end of 
a median follow up of 30 months, patients who achieved 
a SVR demonstrated a signiﬁ  cantly better outcome than 
nonresponders and controls. As compared with the baseline 
value, the Child-Pugh score signiﬁ  cantly improved at the end 
of follow-up in SVR patients and worsened both in nonre-
sponders and in controls. There were nine deaths in the group 
of nonresponders and 15 among controls, mainly related to 
liver failure; moreover, one and four patients underwent liver 
transplantation due to progressive liver failure and/or devel-
opment of HCC, respectively. All 13 patients who achieved 
SVR survived without LT.
Summary and conclusions
The strongest rationale to treat HCV-positive cirrhotics on 
the waiting list for LT is provided by the evidence that those 
who achieve SVR can beneﬁ  t both in term of liver func-
tion, which improves, and HCV recurrence rate in the graft, 
which decreases. Furthermore, at least for a few patients, 
just being HCV RNA negative while on treatment at the 
time the transplant operation is performed may be sufﬁ  cient 
to prevent post transplant HCV recurrence (Kuo et al 2006). 
It is important to note, however, that these results have been 
obtained in small and uncontrolled clinical studies, which 
enrolled overall less than 300 patients with a relative short 
period of follow-up. For these reasons, to date, to treat with 
antiviral therapy all HCV-positive patients who are listed 
for LT can not be recommended. Rather, these observa-
tions should stimulate a very important debate in the liver 
transplantation community, ie, if the actual organ allocation 
policy should be changed, conferring priority in the waiting 
list to HCV-positive patients treated with antiviral therapy 
who achieve virologic endpoints, either on or off treatment. 
Performing the LT when serum HCV RNA is undetectable 
could represent a promising way to prevent HCV recurrence, 
that is the most important predictor of reduced survival post 
LT. The rate of SVR is inﬂ  uenced, as in immunecompetent 
patients treated for chronic hepatitis C, by viral load at 
baseline, slope of HCV RNA decline during treatment and, 
most importantly, HCV genotype. In particular, the risk-
beneﬁ  t of antiviral treatment in cirrhotic patients infected by 
HCV genotype 1 is unclear, since SVR rates are extremely 
low. Since the tolerability of antiviral therapy in these 
very difﬁ  cult to treat patients is limited, and, independently 
of neuthrophil counts, life threatening infections are not 
uncommon, it is often necessary to reduce the doses of both 
interferon and ribavirin. Moreover, only a limited proportion 
of patients with advanced and decompensated liver disease 
awaiting liver transplantation are eligible for therapy; they 
should not be treated outside clinical trials, to be conducted, 
under strict surveillance, preferably in experienced centers. 
The best way to manage antiviral therapy in HCV-positive 
patients awaiting LT is probably to start treatment as soon as 
patients are registered in the LT waiting list; this may allow 
the patients to be given a possible life-line, if their disease 
is to get worse sooner then expected. Furthermore, antiviral 
treatment should probably be stopped in the absence of early 
antiviral response. The subgroup of patients who could gain 
most from antiviral therapy before transplantation is that of 
patients with HCV-related Child-Pugh class A cirrhosis with 
HCC, preferentially related to HCV genotype 2 or 3 infection, 
scheduled to obtain an early liver transplant from a deceased 
donor or awaiting living donor LT.
Several questions remain unanswered and represent the 
goals of future studies. First of all, since SVR rates in HCV-
positive patients awaiting LT treated with the combination 
of standard interferon plus ribavirin remain suboptimal, large 
clinical trials evaluating the efﬁ  cacy of the combination of 
pegylated interferons with ribavirin are urgently needed. 
Secondly, it should be investigated whether the systematic 
use of GCSF and erythropoietin in preventing cytopenias 
during antiviral treatment allows higher SVR rates. A third, 
very important issue regards the possible beneﬁ  t related to 
longer duration of antiviral treatment employing reduced 
doses of standard or pegylated interferon with or without 
ribavirin in terms of slowing ﬁ  brosis progression, in the 
absence of HCV clearance. Recent data coming from the 
HALT-C clinical trial (Everson et al 2006) clearly showed 
that patients with advanced liver diseases (ie, cirrhosis and 
platelets count 125000/mm3) previously non responders to 
antiviral therapy, when retreated with pegylated interferon 
α-2a in combination with ribavirin, achieved a SVR only in 
9% of cases. Importantly, a beneﬁ  t in reducing the progres-
sion of liver disease could be demonstrated only for patients 
who achieved a SVR. The HALT-C trial, therefore, does not Therapeutics and Clinical Risk Management 2008:4(3) 603
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support the strategy to retreat for longer periods of time HCV 
cirrhotic patients, non responders to previous treatments, as 
far as the aim of treatment is to stop the progression of liver 
disease. Finally, the poor tolerability and limited efﬁ  cacy of 
current treatment strategies highlight the need for alterna-
tive drugs able to induce a more vigorous HCV viral decline 
without prohibitive side effects. Several promising new 
compounds administered orally have been discovered and 
are currently undergoing clinical development. In particular, 
two HCV NS3 serine protease inhibitors, named bocepravir 
(Schering-Plough, USA) and telaprevir (Vertex Pharmaceuti-
cal, USA), alone or in combination with pegylated interferon, 
determine a 2 to 4 log10 reduction in HCV viral load along 
a short period of time, although with rapid insurgence of 
escape mutants. In LT centres where the time of the transplant 
operation can be predicted with reasonable accuracy, potent 
antiviral regimens including these new drugs might prove to 
be most effective when used, for a limited period of time, by 
HCV patients on the waiting list.
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